Numerous studies suggest that EZH2 is aberrantly overexpressed in several types of cancer, particularly metastasic breast and prostate cancer, and EZH2 overexpression promotes cell proliferation, invasion and metastasis (19–21). Here, EZH2 is linked to cancer.